Paraneoplastic Flashcards
• Disorders that accompany benign or malignant
diseases but are not directly related to mass effects or invasion
PARANEOPLASTIC SYNDROME:
ENDOCRINE/HEMATOLOGIC
Tumors of neuroendocrine origin, such as small
cell lung carcinoma (SCLC) and carcinoids,
produce a wide array of ____ and are
common causes of paraneoplastic syndromes.
peptide hormones
(expression of a hormone from its normal
tissue of origin)
o For example, ACTH of the pituitary
eutopic
hormone production from an atypical tissue source -For example, the squamous lung CA o Conveys abnormal physiology associated with neoplastic hormone production o Not fully understood
Ectopic
is often characterized by abnormal regulation of hormone production (e.g., defective feedback control) and peptide processing.
Ectopic
• Occurs in up to 20% of patients with cancer.
• Most common in cancers of lung, head and neck,
skin, esophagus, breast, genitourinary, multiple
myeloma, lymphomas
• PTHrP production probably cause osteolysis and
hypercalcemia
HUMORAL HYPERCALCEMIA OF MALIGNANCY (HMM)
Another cause of HHM is excess production of
1,25- dihydroxyvitamin D
o Structurally related to PTH and binds to the
PTH receptor, explaining the similar
biochemical features of HHM and
hyperparathyroidism
o Plays a key role in skeletal development and
regulates cellular proliferation and
differentiation in other tissues, including skin,
bone marrow, breast, and hair follicles
PTHrP
HMM is stimulated by:
- Hedgehog pathways
- Gli transcription factors
- TGF-ß
- Ras oncogene
- Loss of p53
HMM clinical manifestations:
Hypercalcemia, fatigue, mental status changes, dehydration, symptoms of nephrolithiasis
is the initial presenting
feature of malignancy
Hypercalcemic
o With a Calcium level of >3.5 mmol/L
(>14 mg/dL)
HMM: Elevated _________ confirms the diagnosis
PTHrP
HMM treatment: Oral phosphorous (250 mg po 3-4x daily) until
serum phosphorus _____
> 1mmol/L (>3 mg/dL)
Saline rehydration to dilute serum calcium and
promote _______
calciuresis
Used for acute management of life thereatening hypercalcemia
Furosemide (loop diuretic)
Used for chronic management of life thereatening hypercalcemia
Bisphosphonates used for chronic treatment;
o Pamidronate 30-90 mg IV
o Zolendronate 4-8 mg IV
o Etidronate 7.5 mg/kg/day po for 3-7 days
o 2-8 U/kg sc every 12 hrs)
o Severe hypercalcemia
Calcitonin
for patients with;
o Lymphoma
o Multiple myeloma
o Leukemia
Glucocorticoids (prednisone 40-100 mg po in 4
divided doses)
Tumor-Association SIADH compensatory mechanisms:
decreased thirst,
suppression of aldosterone, production of atrial
natriuretic peptide